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Abstract 
The  PI3K/Akt/mTOR  and  JAK/STAT3  signaling  pathways  are  important  for  regulating 
apoptosis, and are frequently activated in cancers. In this study, we targeted STAT3 and 
mTOR in human hepatocellular carcinoma Bel-7402 cells and examined the subsequent al-
terations in cellular apoptosis. The expression of STAT3 was silenced with small interfering 
RNA (siRNA)-expressing plasmid. The activity of mTOR was inhibited using rapamycin. 
Following treatment, Annexin V/propidium iodide staining followed by flow cytometry and 
Hoechst33258 immunofluorescence staining was used to examine cellular apoptosis. JC-1 
staining was used to monitor depolarization of mitochondrial membrane (ΔΨm). Further-
more, the expression of activated caspase 3 protein was analyzed by Western blotting. 
Compared to non-treated or control siRNA-transfected cells, significantly higher levels of 
apoptosis were detected in siSTAT3-transfected or rapamycin-treated cells (P < 0.05), which 
was further enhanced in cells targeted for both molecules (P < 0.05). The pro-apoptotic ef-
fects were accompanied with concomitant depolarization of mitochondrial membrane and 
up-regulation of activated caspase 3. Combined treatments using rapamycin and STAT3 gene 
silencing significantly increases apoptosis in Bel-7402 cells, displaying more dramatic effect 
than any single treatment. This study provides evidence for targeting multiple molecules in 
cancer therapy. 
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most 
common malignancy worldwide and HCC-associated 
annual mortality ranks the third among all tumors(1). 
Its incidence, however, is still on the rise, and is pre-
dicted to plateau between 2015 and 2020(2). Despite 
the advancement of different therapeutic approaches, 
such  as  surgical  resection,  liver  transplantation,  in-
terventional therapy, and percutaneous ablation, im-
provements in patients’ outcomes are still quite lim-
ited(3). Therefore, there is an urgent need to develop 
novel therapies that effectively target the pathological 
alterations underlying HCC.  
In  complex  biological  systems,  cells  communi-
cate  with  their  microenvrionment  through  inter-
twined regulatory signaling networks(4). In response 
to exogenous signals, cells differentiate, proliferate, or 
undergo  cell  death/apoptosis  in  order  to  maintain 
constant  numbers  and  support  organ  functions(5). 
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Biological homeostasis in cell growth is achieved and 
fine-tuned by activating, as well as inhibitory signal-
ing  pathways.  The  constitutive  functioning  of  the 
former  and/or  the  diminished  performance/loss  of 
the latter causes sustained signal transduction leading 
to uncontrolled cell proliferation, resistance to apop-
tosis  and  subsequently,  malignant  growth(6).  Accu-
mulating evidence demonstrates that abnormalities in 
many  signaling  pathways  are  associated  with  the 
pathogenesis of HCC. 
Mammalian target of rapamycin (mTOR) is a key 
molecule  in  the  phosphatidyl  inositol  3  kinase 
(PI3K)/protein kinase B (PKB/Akt)/mTOR signaling 
pathway  that,  through  the  activation  of  various 
downstream targets, critically regulates cell prolifera-
tion, cell cycle progression, gene transcription, protein 
synthesis,  and  cellular  apoptosis(7).  mTOR  is  acti-
vated  by  multiple  stimuli  including  growth  factors 
and nutrients, which act sequentially through recep-
tor tyrosine kinases (RTKs), PI3K, and PKB/Akt sig-
naling cascade. Previous studies indicate that mTOR 
is  frequently  (67%,  37/55)  overexpressed  in  human 
HCCs,  as  detected  by  real-time  reverse  transcrip-
tase-polymerase chain reaction (RT-PCR)(8), and con-
sistently, the mTOR pathway is activated in 40-50% of 
HCC patients(9). 
The signal transducer and activator, STAT3 reg-
ulates  the  expression  of  target  genes  involved  in 
cell-cycle  progression  and  apoptosis,  and  promotes 
cellular transformation as well as abnormal cell pro-
liferation(10,11).  The  deregulation  and  constitutive 
activation of STAT3 are frequently observed in a large 
number of primary tumors and cancer-derived cells 
including  hematologic  malignancies,  breast  cancer, 
prostate cancer, and HCC (12). 
Studies have shown that mTOR phosphorylates 
STAT3 at Ser727, which is required for the latter to 
maximally  activate  the  transcription  of  target 
genes(13). In light of the crosstalk between mTOR and 
STAT3,  and  their  frequent  activations  in  HCC,  we 
wanted  to  explore  the  functional  consequences  of 
targeting these two molecules on cellular apoptosis. 
To  accomplish  this,  pGC-siSTAT3  was  transfected 
into  Bel-7402  cells  using  Lipofectamine  2000,  si-
lencing  the  expression  of  STAT3  to  inhibit  the 
JAK/STAT3  signaling  pathway.  meanwhile  we  in-
hibited the phosphorylation of mTOR using rapamy-
cin to inhibit the PKB/Akt/mTOR signaling pathway. 
We  showed  that  targeting  either  molecule  signifi-
cantly promotes apoptosis in HCC cells Bel-7402, and 
a  further  enhancement  of  apoptosis  was  achieved 
when both molecules were targeted.  
Material and Methods 
Cell culture and reagents 
Human HCC cells Bel-7402 were obtained from 
the  Research  Laboratory  (Department  of  General 
Surgery,  the  First  Hospital  of  Jilin  University).  The 
cells were propagated in Dulbecco’s Modiﬁed Eagle’s 
Medium  (DMEM,  HyClone,  Logan,  UT)  supple-
mented  with  10%  fetal  bovine  serum  (Gemini 
Bio-Products,  West  Sacramento,  CA),  100  units/mL 
penicillin,  and  100  units/mL  streptomycin  (Invitro-
gen, Carlsbad, CA). All cell lines were maintained in a 
cell  culture  incubator  at  37°C  in  humidified  atmos-
phere of 5% CO2, with media changed every three to 
four  days.  Cells  were  collected  by  trypsinization  at 
70–80%  confluence.  β-actin  (C4,  sc-47778)  antibody 
was  purchased  from  Santa  Cruz  (Santa  Cruz,  CA), 
mTOR,  phosphorylated  p-mTOR  (Ser  2448),  and 
cleaved  caspase  3  (p17)  antibodies  were  from  Cell 
Signaling  (Beverly,  MA).  STAT3  (Ab-727)  antibody 
was  from  KeyGEN  (Nanjing,  China).  The  Goat  an-
ti-Mouse  IgG  -HRP  (EarthOx)  and  the  Goat  an-
ti-Rabbit  IgG-HRP  (Pierce)  as  secondary  antibod-
ies.The mTOR-speciﬁc inhibitor, rapamycin was from 
Alexis (Alexis, San Diego, CA). 
Plasmid construction 
An  oligonucleotide  duplex  targeting  2,144  to 
2,162  of  human  STAT3  mRNA  sequence  (GenBank 
accession number NM_0003150) was synthesized by 
Shanghai  Sangon  (Shanghai,  China)  as  follows:  for-
ward,  5'-AAGCAGCAGCTGAACAACATGTTCAA 
GAGACATGTTGTTCAGCTGCTGCTT-3',  and  re-
verse,  5'-AAGCAGCAGCTGAACAACATGTCTCTT 
GAACATGTTGTTCAGCTGCTGCTT-3'.  This  oligo-
nucleotide contains a sense strand of 19 nucleotides 
followed by a short spacer (TTCAAGAGA), an anti-
sense strand, and five Ts that act as a RNA polymer-
ase  III  transcriptional  stop  signal.  The  duplex  was 
cloned  into the pGCsi.U6/neoRFP plasmid (the La-
boratory  of  General  Surgery  Department,  the  First 
Hospital  of  Jilin  University)  to  generate 
pGC-siSTAT3.  The  resulting  plasmid  was  trans-
formed  into  E.  coli  JM109  cells,  purified  using  the 
plasmid miniprep purifcation system B (BioDev, Bei-
jing, China), and then veriﬁed by  sequencing. As a 
negative  control,  a  control  siRNA  oligonucleotide 
duplex targeting no known human genes was used: 
forward,  5'-CCGGTTCTCCGAACGTGTCACGTTT 
CAAGAGAACGTGACACGTTCGGAGAATTTTTG-
3',  and  reverse,  5'-AATTCAAAAATTCTCCGAA 
CGTGTCACGTTCTCTTGAAACGTGACACGTTCG
GAGAA-3'. Int. J. Med. Sci. 2012, 9 
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Transfections and treatments of cells 
pGC-siSTAT3  (0.8μg)and  pGC-siCtrl  plasmids 
(0.8μg) were separately transfected into Bel-7402 cells 
(2×105cells  per  well,  24-well  plate)  using  Lipofec-
tamine  2000  (Invitrogen)(2.0μL)  following  the 
manufacturer’s instructions for 4 hours, after which 
time the transfection medium was replaced with reg-
ular growth medium. Cells were treated as indicated 
at 24 h after transfection. The transfection efﬁciency 
was determined by observing the expression of RFP 
reporter  using  an  Olympus  IX  inverted  microscope 
with a ﬂuorescence attachment.  
For  rapamycin  treatment,  cells  were  incubated 
with 109 nmol/L rapamycin for 48 h at 37°C in hu-
midified atmosphere of 5% CO2. 
Flow cytometry (FCM) analysis for apoptosis 
determination 
Annexin-V/propidium iodide (PI) double assay 
was performed using the Annexin V-FITC Apoptosis 
Detection kit (KeyGEN Biotech). Following treatment, 
cells were released from the culture dish with trypsin 
and washed twice with PBS. 1 × 106 cells were resus-
pended  in  500-μL  binding  buffer  and  stained  with 
5-μL FITC-labeled Annexin-V according to the man-
ufacturer’s  instructions.  5-μL  propidium  iodide  (PI) 
was added and allowed to incubate with cells for 10 
min at room temperature in the dark. After further 
washes with PBS, cells were subjected to FCM analy-
sis using BD FACSCalibur (BD Biosciences, San Jose, 
CA).  The  data  were  analyzed  using  CellQuest  data 
acquisition and analysis software (BD Biosciences).  
Hoechest33258 staining 
Cells  were  washed  twice  with  PBS  and  fixed 
with 4% paraformaldehyde for 30 minutes. Following 
further  PBS  wash,  cells  were  incubated  in  100-μL 
Hoechst33258 solution for 10 minutes in the dark at 
37°C. The solution was then removed and cells were 
washed  twice  with  PBS  and  analyzed  using  an  in-
verted fluorescence microscope.  
Mitochondrial membrane potential (ΔΨm) 
assay using fluorescence microscopy 
To  monitor  the  alterations  in  mitochondrial 
membrane  potential,  JC-1  dye  (5,5′,6,6′-tetrachloro- 
1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide, 
Invitrogen) was applied to Bel-7402 cells (2 μL/mL 
medium) and incubated with cells for 20 min at 37 °C, 
5% CO2. JC-1 forms aggregates in healthy mitochon-
dria and emits red fluorescence (excitation/emission 
485/580 nm). In apoptotic and necrotic cells, JC-1 does 
not  aggregate  and  exists  as  monomeric  form  with 
green fluorescence (excitation/emission 485/530 nm) 
that  indicates  the  loss  of  mitochondrial  membrane 
potential/depolarization.  After  the  incubation,  the 
dye was aspirated from the plates, and the plates were 
washed three times with 1× JC-1 buffer and examined 
with a fluorescent microscope (Leica DMI 4000, Ger-
many) using both red and green channels. The data 
are expressed as the percentage of red fluorescence 
counts of both red and green fluorescent counts. 
Protein extractions and Western blotting  
Cells  were  rinsed  once  with  ice-cold  PBS  and 
lysed in ice-cold cell lysis buffer (Walterson, London, 
UK) containing complete protease inhibitors cocktail 
(Sigma-Aldrich, Germany). The protein concentration 
was  determined  using  the  BCA  protein  assay  kit 
(KeyGEN Biotech) using a c-globulin standard curve. 
Proteins  were  separated  on  7.5–12%  sodium 
dodecyl sulfate polyacrylamide (SDS-PAGE) gels, and 
transferred to a PVDF membrane. The membrane was 
blocked  with  5%  skim  milk  in  TBS-T  (10  mM 
Tris-HCl, 150 mM NaCl, 0.25% Tween 20, pH 7.5) at 
room  temperature  for  2  h  followed  by  appropriate 
primary antibody in TBS and 5% skim milk overnight 
at 4°C. After washing with TBS-T, the membrane was 
incubated with a secondary antibody in TBS-T buffer 
for 2 h at room temperature, followed by three washes 
with TBS-T. Protein bands were visualized using the 
enhanced  chemiluminescence  ECL  substrate  (Wal-
terson,  London,  UK)  and  quantified  using  the  Vi-
sionWorksLS software (UVP, LLC Upland, CA). All 
primary antibodies were used at 1:500 and secondary 
antibodies at 1:1000. 
Statistical analysis 
All  experiments  were  independently  repeated 
three times and the results are presented as mean ± 
SD.  Statistical  analyses  of  the  differences  between 
groups were performed by using the SigmaStat sta-
tistical software package (SPSS Inc., Chicago, IL). The 
criterion for statistical significance was P < 0.05. 
Results  
Rapamycin significantly inhibits the phosphor-
ylation of mTOR in Bel-7402 cells.  
Following treatment with 109 nmol/L rapamy-
cin (Rap) for 48 h at 37°C, the p-mTOR level was ex-
amined by Western blotting and compared with that 
in non-treated control (Ctrl) cells. As shown in Figure 
1A, p-mTOR level was significantly reduced in Rap 
cells, as compared to in Ctrl cells (P < 0.05), while the 
level of total mTOR was not dramatically affected (P > 
0.05).  Int. J. Med. Sci. 2012, 9 
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STAT3 siRNA specifically knocks down STAT3 
protein level in Bel-7402 cells. 
To  reduce  the  expression  of  STAT3,  we  trans-
fected Bel-7402 cells with pGC-siSTAT3 (siSTAT3). As 
a control, pGC-siCtrl plasmid was transfected (siCtrl). 
Compared  to  the  non-transfected  cells  (Ctrl),  siCtrl 
cells showed no reduction of STAT3 level, while siS-
TAT3 cells exhibited approximately 50% reduction in 
STAT3 level (P < 0.05, Figure 1B). 
Targeting STAT3 and/or mTOR promotes 
cellular apoptosis in Bel-7402 cells. 
After Bel-7402 cells were transfected with either 
pGC-siSTAT3  or  pGC-siCtrl  and  treated  in  the  ab-
sence  or  presence  of  rapamycin,  cellular  apoptosis 
was first examined by Annexin V and PI staining fol-
lowed by FCM analysis (Figure 2A). The percentage 
of apoptotic cells, as represented by dual PI and An-
nexin  V  positivity,  ranged  from  9.22±0.38%  in 
non-treated  Bel-7402  cells  (Ctrl)  to  16.47±1.04%  in 
siCtrl,  42.73±0.88%  in  siSTAT3,  43.03±0.46%  in  ra-
pamycin-treated  (Rap),  45.44±0.59%  in  siCtrl+Rap, 
and  60.22±0.87%  in  siSTAT3+Rap  cells  (Figure  2B). 
Targeting either STAT3 with siRNA or mTOR with 
rapamycin  significantly  promoted  apoptosis,  as 
compared to non-treated or siCtrl-transfected cells (P 
<  0.05).  This  pro-apoptotic  effect  was  further  en-
hanced when both molecules were targeted (P < 0.05). 
Consistent with FCM analysis, Bel-7402 cells also 
presented  typical  apoptotic  morphology  following 
treatment with siSTAT3, rapamycin, or both (Figure 
3). These treatments not only reduced the number of 
cells remaining attached to the plate but also led to 
characteristic changes of chromatin condensation and 
nuclear  fragmentation,  with  the  most  dramatic 
changes observed in cells treated with both siSTAT3 
and rapamycin. 
 
 
 
Figure 1: Rapamycin inhibits the phosphorylation of mTOR and siSTAT3 specifically knocks down the level of STAT3 in Bel-7402 cells. 
A. Cells were treated without (Ctrl) or with 109 nmol/L rapamycin (Rap) for 48 h. The expression levels of phosphorylated mTOR 
(p-mTOR), total mTOR, and β-actin (as internal control) were examined by Western blotting. A representative image is shown on the 
left, and quantifications of p-mTOR/β-actin as well as mTOR/β-actin on the right. *P < 0.05, as compared to Ctrl cells. B. Cells were 
transfected with either pGC-siSTAT3 or pGC-siCtrl. The expression level of STAT3 was determined by Western blotting and compared 
to  that  in  non-treated  cells  (Ctrl).  A  representative  image  is  shown  on  the  left,  and  quantification  of  STAT3/β-actin  as  well  as 
mTOR/β-actin on the right. *P < 0.05, as compared to Ctrl cells. 
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Figure  2:  Targeting  STAT3  and/or  mTOR  pro-
motes  cellular  apoptosis  in  Bel-7402  cells.  Cells 
were treated as indicated at 24 h after transfection 
using Lipofectamine 2000  for 4 hours. For ra-
pamycin treatment, cells were incubated with 109 
nmol/L rapamycin for 48 h at 37°C in humidified 
atmosphere  of 5%  CO2.  Cells  were  stained with 
Annexin V (FL1 channel) and PI (FL2 channel), and 
analyzed  by  FCM.  A.  A  representative  FCM  plot 
from each group is shown. Ctrl, non-treated control 
cells;  siCtrl,  cells  transfected  with  control  siR-
NA-expressing plasmid; siSTAT3, cells transfected 
with siSTAT3-expressing plasmid; Rap, cells treated 
with rapamycin; siCtrl+Rap, cells transfected with 
control siRNA-expressing plasmid and treated with 
rapamycin;  siSTAT3+Rap:  cells  transfected  with 
siSTAT3-expressing  plasmid  and  treated  with  ra-
pamycin. B. Percentage of dual Annexin V+PI+ cells 
from three independent experiments were quanti-
fied and  presented as  mean  ± SD.  *P <  0.05,  as 
compared to Ctrl and siCtrl groups; #P < 0.05, as 
compared to all other groups. 
 
 
 
 
 
 
 
 
 
 
Figure 3: Targeting STAT3 and/or mTOR promotes cellular apoptosis in Bel-7402 cells. Cells were treated as indicated, fixed with 4% 
paraformaldehyde for 30 minutes. Following further PBS wash, cells were incubated in 100-μL Hoechst33258 solution for 10 minutes in 
the dark at 37°C, and imaged under inverted fluorescence microscope (× 400), with representative image from each group presented. Int. J. Med. Sci. 2012, 9 
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Targeting STAT3 and/or mTOR leads to mi-
tochondrial depolarization in Bel-7402 cells.  
To  examine  whether  targeting  STAT3  and/or 
mTOR induces collapse of mitochondrial membrane 
potential (ΔΨm), we used JC-1, a cationic mitochon-
drial  vital  dye  exhibiting  potential-dependent  accu-
mulation in mitochondria, as represented by a shift of 
fluorescence emission from red in normal polarized 
mitochondria to green in abnormal depolarized mi-
tochondria.  As  shown  in  Figure  4,  targeting  either 
STAT3 or mTOR significantly reduced the percentage 
of  cells  emitting  red  fluorescence  (59.06±1.89%  for 
siSTAT3 and 57.25±1.93% for Rap cells, respectively), 
as  compared  to  non-treated  control  or 
siCtrl-transfected  cells  (91.33±1.78%  for  Ctrl  and 
89.90±1.92% for siCtrl cells, P < 0.05). Targeting both 
molecules resulted in the least number of cells with 
red fluorescence (27.28±1.82%, P < 0.05, as compared 
to  all  other  groups),  suggesting  that  disruption  of 
mitochondria is, at least partially, responsible for the 
apoptotic  effects  induced  by  targeting  both  STAT3 
and mTOR.  
Targeting STAT3 and/or mTOR increases 
cleaved caspase 3 levels in Bel-7402 cells.  
Besides  mitochondrial  depolarization,  the  ex-
pression  of  cleaved/activated  caspase  3  in  Bel-7402 
cells following different treatments was analyzed by 
Western  blotting  (Figure  5).  The  highest  level  was 
detected in cells targeted for both STAT3 and mTOR 
(siSTAT3+Rap), followed by those targeted for either 
molecule (siSTAT3, Rap, or siCtrl+Rap), and the low-
est level was observed in non-treated control (Ctrl) or 
siCtrl-transfected (siCtrl) cells.  
 
 
 
 
Figure 4: Targeting STAT3 and/or mTOR leads to mitochondrial membrane depolarization in Bel-7402 cells. A. Cells were treated as 
indicated, stained with JC-1 dye, incubated with cells for 20 min at 37 °C, 5% CO2 and imaged under fluorescence microscope (× 200) at 
the emission wavelength of 580 nm (red, upper panels) and 530 nm (green, lower panels). A representative image from each group is 
shown. B. Percentage of red fluorescent cells from three independent experiments were quantified and presented as mean ± SD. *P < 0.05, 
as compared to Ctrl and siCtrl groups; #P < 0.05, as compared to all other groups. 
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Figure 5: Targeting STAT3 and/or mTOR increases cleaved caspase 3 levels in Bel-7402 cells. A. Cells were treated as indicated and 
Proteins were extracted. The expression of cleaved caspase 3 was determined by Western blotting, with representative gel image shown. 
β-actin expression was determined as internal control. B. Western signal intensity of cleaved caspase 3 was quantified using the Vi-
sionWorksLS software, standardized to the intensity of β-actin, and presented as mean ± SD from three independent experiments. *P < 
0.05, as compared to Ctrl and siCtrl groups; #P < 0.05, as compared to all other groups. 
 
Discussion  
mTOR  is  a  large  molecular-weight  (approxi-
mately 300 kDa) Ser/Thr protein kinase belonging to 
the  family  of  phosphatidyl  inositol  kinase  like  pro-
teins and mediates intracellular signaling related to 
cell  growth,  proliferation,  and  differentiation.  Acti-
vated PI3K in response to several stimuli catalyzes the 
phosphorylation  of  phosphatidyl  inositol  3,  4  di-
phosphate (PIP2) to phosphatidyl inositol 3, 4, 5 tri-
phosphate (PIP3), which binds to the pleckstrin ho-
mology (PH) domain of PKB/Akt, recruiting and ac-
tivating PKB/Akt. Phosphorylated PKB/Akt directly 
or indirectly phosphorylates mTOR and controls the 
level of p-Mtor(14). Subsequently, p-mTOR regulates 
important cellular processes such as protein synthesis 
and cell proliferation through the activation of down-
stream targets including 4E-BP1 and S6K1. Consistent 
with its functions in regulating cell growth, mTOR is a 
crucial molecule in the generation and development 
of many tumors, rendering it an important target for 
tumor gene therapy(15,16).  
Rapamycin  is  a  macrocyclic  lactone  antibiotic 
produced  by  Streptomyces  hygrocopicus  and  was 
first discovered on Easter Island in a natural product 
screen for fungicides(17). It binds to the FK506 bind-
ing protein (FKBP)/rapamycin-binding (FRB) domain 
in mTOR to block the phosphorylation of downstream 
effectors, including S6K1 and 4E-BP1, and thus inhib-
its the transition from G1 to S phase cell cycle (18). 
Previous studies suggested that rapamycin has anti-
cancer activity in numerous tumor types(19). 
Many evidence showed that STAT3 plays a cru-
cial role in oncogenesis. STAT3 acts downstream of 
cytokine  receptors, growth  factor  receptors  and  cy-
toplasmic tyrosine kinases. Activation of STAT3 oc-
curs  by  the  JAK  (Janus  Kinase)  that  are  associated 
with  cytokine  receptors,  upon  ligand  binding  with, 
e.g.  growth  factors,  hormones  and  oncogenes  (21). 
The  phosphorylated  STAT3  carries  signals  into  the 
nucleus and binds to specific DNA response elements 
to regulate the transcription of many genes, such as 
Cyclin  D,  myc,  Bcl-xl  and  Mcl-1  (20).  Consequently, Int. J. Med. Sci. 2012, 9 
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STAT3  is  significantly  involved  in  the  proliferation 
and anti-apoptosis of cancer cells. 
In  this  study,  we  applied  RNAi  to  specifically 
down-regulate the expression of STAT3. Here we ob-
tained 50% inhibition of STAT3 expression by trans-
fecting Bel -7402 cells with siRNA targeting specifi-
cally  STAT3.  STAT3  knockdown  was  incomplete. 
Since  requirements  for  efficient  shRNA  biogenesis 
and  target  suppression  are  largely  unknown,  many 
predicted  shRNAs  fail  to  efficiently  suppress  their 
target(22). As reported before, mTOR is involved in 
the  serine  phosphorylation  of  STAT3  (23).Likewise, 
the PI3K/Akt/mTOR pathway inhibitors, rapamycin, 
abolished  the  phosphorylation  effect  of  mTOR.  The 
dephosphorylation  of  mTOR  would  more  inhibited 
activation of STAT3. 
Hepatocarcinogenesis  is  strongly  linked  to  de-
regulation  of  major  signaling  pathways  such  as 
PI3K/Akt/mTOR  and  JAK/STAT3(24,25).  In  this 
study,  we  explored  the  potential  of  targeting  these 
two signaling pathways and their effects on regulat-
ing cellular apoptosis. Apoptosis, or programmed cell 
death, is a complicated, genetically determined pro-
cess involved in the development and maintenance of 
homeostasis in multicellular organisms. The capabil-
ity of evading apoptosis is critical for the development 
and sustained growth of many, perhaps all, cancers, 
and the induction of apoptosis has now been consid-
ered as an important approach for cancer therapy(26). 
In this study, we showed that targeting either STAT3 
or mTOR significantly induced apoptosis in Bel-7402 
cells; in addition, the combined treatment displayed 
further  enhancement  in  apoptosis,  as  demonstrated 
by both FCM and Hoechst33258 staining. 
It is known that apoptosis can be triggered in a 
cell  through  either  the  extrinsic/death  recep-
tor-mediated  or  intrinsic/mitochondria-mediated 
pathway. Thus, we further characterized the nature of 
apoptosis induced by targeting STAT3 and/or mTOR. 
We  found  that  following  treatment  with  either  siS-
TAT3 or rapamycin, there was significant decrease in 
the mitochondrial  membrane potential, as indicated 
by the decrease in JC-1 dye aggregates (red) and in-
crease  in  its  monomers  (green).  The  mitochondrial 
depolarization became even dramatic with combined 
treatments,  suggesting  that  both  STAT3  and  mTOR 
are essential for maintaining mitochondrial integrity. 
The ΔΨm depolarization triggers the release of cyto-
chrome  c  that  activates  caspases  in  the  cytosol  and 
subsequently  initiates  the  apoptotic  cascade.  Con-
sistently, Western blot showed that the expression of 
cleaved/activated  caspase3  by  treatment  with  both 
siSTAT3 and rapamycin is up-regulated, significantly 
higher than that in other groups. 
Although  the  combined  treatments  with  siS-
TAT3  and  rapamycin  increased  apoptosis,  depolar-
ized the mitrochondrial membrane, and up-regulated 
cleaved  caspase  3,  to  a  greater  extent  than  either 
treatment alone, we did not observe an additive effect. 
We made the conjecture that the cause involves two 
factors.  On  one  hand,  the  improved  pro-apoptotic 
activity  of  combined  treatments  suggests  that  these 
two signaling pathways do not converge on the exact 
same targets to regulate apoptosis. On the other hand, 
the short of additive effects implies that they do not 
work mutually exclusively in modulating apoptosis. 
This  is  consistent  with  a  previous  observation  that 
mTOR  directly  phosphorylates  STAT3,  which  is  re-
quired for the optimal activity of the latter to regulate 
downstream targets.  
In  conclusion,  the  present  work  demonstrates 
that  combined  treatments  using  rapamycin  and 
STAT3 gene silencing more potently promotes apop-
tosis in Bel-7402 cells, as compared to targeting either 
molecule alone. This study lays the groundwork for 
future  development  of  multi-target  drugs  in  cancer 
therapy.  
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